April 2007 | Oncology & Biotech News

BIO-BUZZ: QUADRAMET�: A New Option for Hormone-Refractory Prostate Cancer?

August 16, 2010

The treatment of hormone-refractory prostate cancer often represents a therapeutic challenge. As the most common malignancy in men and the second-leading cause of cancer death in the US, the number of patients requiring posthormonal therapy is increasing.

The Industry Insider: April 2007

August 13, 2010

Companies in the news: 1) AVAX and CTCA Collaborating for Cancer Therapies 2) Full Speed Ahead for GPC Biotech's Satraplatin 3) Bristol-Myers Squibb Company / Adnexus Therapeutics: Collaboration for New Oncology Compounds, and more

Flash Findings: A Global View of Biotechnology

August 13, 2010

The Organisation for Economic Co-operation and Development (OECD) (www.oecd.org) %u201Cis a group of 30 member countries sharing a commitment to democratic government and the market economy. Best known for its publications and its statistics, its work covers economic and social issues from macroeconomics, to trade, education, development and science and innovation.%u201D

The Academy: April 2007

August 13, 2010

The Academy delivers the latest news on biotechnology and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther into knowledge and discovery.

Physicians' Financial News for April 2007

August 13, 2010

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotechnology sector. In this issue: 1) Avalon Could Earn More Than $200M in Deal with Merck & Co. 2) OXiGENE Sets Fiscal 2007 Priorities 3) Genentech Shares Fall Nearly 3% on Avastin Study, and more

The Virtual Window: Clinical Trial Reports--April 2007

August 13, 2010

The Clinical Trials reported in this issue include: PHASE I: 1) Cell Genesys and Medarex Remain Positive on Combination Immunotherapy Study 2) Active Biotech Achieves Success with TASQ for Prostate Cancer PHASE II: 1) Myriad Initiates Evaluation of Brain Cancer Drug that Crosses the Blood-Brain Barrier 2) Second Lung Cancer Trial Adds Data to Novel Therapy, and more

Moving Forward: Building a Community with Every Issue

August 12, 2010

We are privileged to bring you such stories as the shrinking oncology workforce and the exciting news about Tykerb (GSK's advanced breast cancer drug) as we continue evolving our publication both in style and content.